Theratechnologies Inc Key Opinion Leader Webinar Transcript
Good morning, and welcome to the Theratechnologies KOL Webinar on the SORT1+ Technology and the TH1902 for Treating Advanced Solid Tumors. (Operator Instructions)
As a reminder, this webinar is being recorded and a replay will be made available on the Theratechnologies website following the conclusion of the event.
I would now like to turn the call over to your host, Paul Lévesque. Please go ahead, sir.
© -
Good morning, everyone, and welcome to the scientific and clinical update. My name is Paul Lévesque, and I am President and CEO of Theratechnologies.
First, today, we'll have Dr. Béliveau, who will review why SORT1 receptor is a novel and important target in cancer therapy. Then we'll have Christian, our Chief Medical Officer, who will present preclinical data, including new data that has never been presented. And then we'll take your questions. But before we do so, I would like to cover a few slides with you.
Next slide, please. I'd
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
